AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL)

CUSIP: 05337G107

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class
Equity / COM
Total 13F shares
15,275,183
Share change
-797,333
Total reported value
$78,969,220
Put/Call ratio
699%
Price per share
$5.17
Number of holders
76
Value change
-$11,332,656
Number of buys
38
Number of sells
29

Quarterly Holders Quick Answers

What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q1 2016

As of 31 Mar 2016, AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by 76 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,275,183 shares. The largest 10 holders included FMR LLC, GREAT POINT PARTNERS LLC, VHCP Management, LLC, NUMERIC INVESTORS LLC, BlackRock Fund Advisors, VANGUARD GROUP INC, SABBY MANAGEMENT, LLC, PRIMECAP MANAGEMENT CO/CA/, BlackRock Institutional Trust Company, N.A., and Connor, Clark & Lunn Investment Management Ltd.. This page lists 76 institutional shareholders reporting positions in this security for the Q1 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.